SAN DIEGO, July 31, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that management will present an update on Obalon at the following upcoming investor conference:

• Andy Rasdal, Chief Executive Officer and Bill Plovanic, Chief Financial Officer of Obalon will present an update on the company at the Canaccord Genuity Growth Conference in Boston, MA on Wednesday, August 9, 2017 at 9:30 am (ET). The presentation, which will occur live at the Intercontinental Hotel, will be concurrently webcast.

The link to the webcast will be available at: http://wsw.com/webcast/canaccord26/obln. A replay of the webcast will be available for 90 days following the presentation.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

For Obalon Therapeutics, Inc.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com

Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com